ClinicalTrials.gg
RecruitingNCT07213973Updated Nov 13, 2026

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 2 interventional study of Povorcitinib in Hidradenitis Suppurativa (HS), sponsored by Incyte Corporation. Recruiting at 28 sites in 2 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 13, 2026Site recruiting status changed2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Hidradenitis Suppurativa by Incyte Corporation — 3 open to participants now, 6 under way, 4 of them phase 3. Hidradenitis Suppurativa · Incyte Corporation.

Planned enrollment
9th of 12
40 · median 391
Started
2026
the only one that year
Phase 2
5 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, this one is the 9th largest by planned enrollment, is the only one that started in 2026, is one of 5 in phase 2, and was the 12th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

3 of the 12 studies in Hidradenitis Suppurativa by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hidradenitis Suppurativa by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.

03

Conditions studied

  • Hidradenitis Suppurativa (HS)

Keywords

  • Hidradenitis Suppurativa
  • HS
  • INCB054707
  • Povorcitinib
  • Acne inversa
  • Hidradenitis
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 12 to \< 18 years at the time of /assent signing.
  • Body weight ≥ 30 kg at both screening and baseline visits.
  • Diagnosis of moderate to severe HS for at least 3 months prior to the screening visit.
  • Total abscess and inflammatory nodule count of at least 5 at both the screening and baseline visits.
  • HS lesions corresponding to refined Hurley Stage IB, IC, IIB, IIC, or III at both the screening and baseline visits.
  • Documented history of inadequate response to at least a 3-month course of at least 1 conventional systemic therapy (oral antibiotic or biologic drug) for HS (or demonstrated intolerance to, or have a to, a conventional systemic therapy for treatment of their HS).
  • Agreement to use .
  • Willing and able to comply with the study protocol and procedures.
  • Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Presence of > 20 draining tunnels (fistulas) at either the screening or baseline visit.
  • Women who are pregnant (or who are considering pregnancy) or breastfeeding.
  • Medical history including thrombocytopenia, coagulopathy or dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
  • Laboratory values outside of the protocol-defined ranges.
  • Further exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Povorcitinib Dose A

    Participants will receive povorcitinib dose A for 54 weeks.

    Drug: Povorcitinib

  • Experimental
    Povorcitinib Dose B

    Participants will receive povorcitinib dose B for 54 weeks.

    Drug: Povorcitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants with Treatment-Emergent Adverse Events (TEAEs)

    TEAE is defined as any AE either reported for the first time or worsening of a pre-existing event after the first dose of study drug up to 30 days after the last dose of study drug.

    Time frame: Baseline through Week 54

  2. Apparent clearance

    Time frame: Up to Week 24

  3. Apparent volume of distribution

    Time frame: Up to Week 24

  4. Apparent oral absorption rate constant

    Time frame: Up to Week 24

  5. Absorption lag time

    Time frame: Up to Week 24

  6. Maximum plasma drug concentration at steady state

    Time frame: Up to Week 24

  7. Average plasma drug concentration at steady state

    Time frame: Up to Week 24

  8. Plasma concentration at steady state for the dosing interval

    Time frame: Up to Week 24

  9. Time to maximum plasma concentration at steady state

    Time frame: Up to Week 24

  10. Terminal half-life

    Time frame: Up to Week 24

Secondary outcomes

  1. Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)

    HiSCR50 is defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count.

    Time frame: 54 weeks

  2. Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)

    HiSCR75 is defined as at least a 75% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count.

    Time frame: 54 weeks

  3. Mean change from baseline in abscess count at each visit

    Defined as mean change of abscess count relative to baseline.

    Time frame: 54 weeks

  4. Mean percentage change from baseline in abscess count at each visit

    Defined as mean percentage change from baseline in abscess count.

    Time frame: 54 weeks

  5. Mean change from baseline in inflammatory nodule count at each visit

    Defined as mean change of inflammatory nodule count relative to baseline.

    Time frame: 54 weeks

  6. Mean percentage change from baseline in inflammatory nodule count at each visit

    Defined as mean percentage change from baseline in inflammatory nodule count.

    Time frame: 54 weeks

  7. Mean change from baseline in draining tunnel count at each visit

    Defined as mean change of draining tunnel count relative to baseline.

    Time frame: 54 weeks

  8. Mean percentage change from baseline in draining tunnel count at each visit

    Defined as mean percentage change from baseline in draining tunnel count.

    Time frame: 54 weeks

  9. Proportion of participants who achieve Skin Pain Numeric Rating Scale (NRS)30 among participants with baseline Skin Pain NRS score ≥ 3

    Defined as participants with a Skin Pain NRS score of at least 3 at baseline and who achieve Skin Pain NRS30, defined as at least a 30% reduction and at least 1-unit reduction from baseline in the Skin Pain NRS.

    Time frame: 54 weeks

  10. Proportion of participants with a ≥ 3-point decrease in Skin Pain NRS score among participants with baseline Skin Pain NRS score ≥ 3

    Participants with a Skin Pain score of at least 3 at baseline and who experience at least a 3-point decrease in Skin Pain score.

    Time frame: 54 weeks

  11. Change from baseline in Children's Dermatology Life Quality Index (CDLQI) score at each visit

    The CDLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days, across symptoms and feelings, leisure, school or holidays, personal relationships, sleep, and treatment.

    Time frame: 54 weeks

07

Study locations

28 of 28 sites recruiting
  • University of Alabama At Birmingham
    Birmingham, Alabama 35233, United States
    Recruiting
  • Medical Dermatology Specialists Phoenix
    Phoenix, Arizona 85006, United States
    Recruiting
  • Saguaro Dermatology
    Phoenix, Arizona 85008, United States
    Recruiting
  • Uconn Health
    Farmington, Connecticut 06030, United States
    Recruiting
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
    Recruiting
  • Skin Research of South Florida, Llc
    Miami, Florida 33173, United States
    Recruiting
  • Trueblue Clinical Research
    Tampa, Florida 33607, United States
    Recruiting
  • Advanced Medical Research Pc
    Sandy Springs, Georgia 30328, United States
    Recruiting
  • Endeavor Health Medical Group
    Skokie, Illinois 60077, United States
    Recruiting
  • Dermatology Skin Cancer Center Leawood
    Leawood, Kansas 66211, United States
    Recruiting
  • Equity Medical
    Bowling Green, Kentucky 42104, United States
    Recruiting
  • Johns Hopkins Univ Schl of Medicine
    Baltimore, Maryland 21205, United States
    Recruiting
  • Boston Childrens Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
  • Oakland Hills Dermatology Pc
    Auburn Hills, Michigan 48326, United States
    Recruiting
  • Wayne State University Physician Group Dermatology
    Detroit, Michigan 48201, United States
    Recruiting
  • Revival Research Institute, Llc Troy
    Troy, Michigan 48084, United States
    Recruiting
  • Washington University
    St Louis, Missouri 63110, United States
    Recruiting
  • Boeson Research Missoula 2825 Fort Missoula Rd
    Missoula, Montana 59804, United States
    Recruiting
  • University of New Mexico Hospital
    Albuquerque, New Mexico 87102, United States
    Recruiting
  • Geisinger Medical Center
    Danville, Pennsylvania 17822, United States
    Recruiting
  • Bellaire Dermatology Associates Bda
    Bellaire, Texas 77401, United States
    Recruiting
  • Texas Dermatology Research Center
    Dallas, Texas 75246, United States
    Recruiting
  • 3A Research Llc West Location
    El Paso, Texas 79902, United States
    Recruiting
  • Jordan Valley Dermatology Center
    South Jordan, Utah 84095, United States
    Recruiting
  • Dermcare Clinic
    Mississauga, Ontario L4W 0C2, Canada
    Recruiting
  • York Dermatology Center
    Richmond Hill, Ontario L4B 1L1, Canada
    Recruiting
  • The Hospital For Sick Children
    Toronto, Ontario M5G 1X8, Canada
    Recruiting
  • Skincare Studio Dermatology Centre
    St. John's, A1E 1V4, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2028, 25 months after the start.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 25 months is above that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2025
First posted
Oct 9, 2025
StartActual
Feb 2, 2026
Primary completionEst.
Mar 25, 2028
CompletionEst.
Mar 25, 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites removed. 3A Research Llc West Location is now Recruiting
Show 2 removed
  • Skin Oasis Dermatology · Gambrills, United States
  • University of Missouri Kansas City · Kansas City, United States
across 2 updates, Oct 9, 2026 – Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    2 sites removed
    Show 2 removed
    • Skin Oasis Dermatology · Gambrills, United States
    • University of Missouri Kansas City · Kansas City, United States
    + 1 other change: verification date
  2. Oct 9, 2026
    3A Research Llc West Location is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07213973
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Feb 2, 2026
Primary completion
Mar 25, 2028 (estimated)
Completion
Mar 25, 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Incyte Corporation Call Center (US)
Contact
medinfo@incyte.com
1.855.463.3463
Incyte Corporation Call Center (ex-US)
Contact
eumedinfo@incyte.com
+800 00027423
Incyte Medical Monitor
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povorcitinib

Start the discussion